Related references
Note: Only part of the references are listed.Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
Zhihong Zeng et al.
BLOOD (2012)
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)
Sergio Amadori et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy
Alexander E. Perl et al.
CLINICAL CANCER RESEARCH (2012)
Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis
S. Fruchon et al.
LEUKEMIA (2012)
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
L. Willems et al.
LEUKEMIA (2012)
Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
Jessica K. Altman et al.
CLINICAL CANCER RESEARCH (2011)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis et al.
CLINICAL CANCER RESEARCH (2010)
Inhibition of rnTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo
Jing Yang et al.
EXPERIMENTAL HEMATOLOGY (2010)
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
N. Chapuis et al.
LEUKEMIA (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
Ryan M. Young et al.
BLOOD (2009)
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
Jerome Tamburini et al.
BLOOD (2009)
Proteomic and Genetic Approaches Identify Syk as an AML Target
Cynthia K. Hahn et al.
CANCER CELL (2009)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Alexander E. Perl et al.
CLINICAL CANCER RESEARCH (2009)
Impaired myelopoiesis in mice lacking the repressors of translation initiation, 4E-BP1 and 4E-BP2
Katie E. Olson et al.
IMMUNOLOGY (2009)
Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells
Chie Nishioka et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation
Meaghan Wall et al.
BLOOD (2008)
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway
Nathalie Carayol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
C. Nishioka et al.
LEUKEMIA (2008)
A critical role for Lyn in acute myeloid leukemia
Ceric Dos Santos et al.
BLOOD (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation
Philippe P. Roux et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR
Nicholas Lehman et al.
FASEB JOURNAL (2007)
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G
Nathan J. Moerke et al.
CELL (2007)
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth
Murali Gururajan et al.
JOURNAL OF IMMUNOLOGY (2007)
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation human myeloid leukemia cells
Bulent Ozpolat et al.
MOLECULAR CANCER RESEARCH (2007)
Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells
Thomas Wossning et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
Ting-Lei Gu et al.
BLOOD (2006)
Syk-dependent mTOR activation in follicular lymphoma cells
Ludivine Leseux et al.
BLOOD (2006)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen
J Moffat et al.
CELL (2006)
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma
B Streubel et al.
LEUKEMIA (2006)
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
A Rinaldi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
A method for high-throughput gene expression signature analysis
David Peck et al.
GENOME BIOLOGY (2006)
mTOR regulates cell survival after etoposide treatment in primary AML cells
Q Xu et al.
BLOOD (2005)
Gefitinib induces myeloid differentiation of acute myeloid leukemia
K Stegmaier et al.
BLOOD (2005)
Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins
XM Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation
K Stegmaier et al.
NATURE GENETICS (2004)
TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways
T Kanie et al.
LEUKEMIA (2004)
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor
CJ Fox et al.
GENES & DEVELOPMENT (2003)
Systematic discovery of multicomponent therapeutics
AA Borisy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis
I Topisirovic et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12)
Y Kuno et al.
BLOOD (2001)
Share Paper
